axelroark

IBB Breakdown After Back Test

ショート
NASDAQ:IBB   iShares Biotechnology ETF
IBB is showing weakness, having broken through a key support area and then failed to recover in day 1 of the back test. Expect to see re-test of 98'ish support, with failure leading to a re-test of December 2018 lows, and perhaps much lower. Bang for buck isn't great here, so we aren't taking the trade, but risk/reward is very good on this move.

免責事項

これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。